Reuters logo
BRIEF-Pharma Mar presents response rate data with PM1183 in patients with lung cancer‍​
September 12, 2017 / 7:29 AM / 9 days ago

BRIEF-Pharma Mar presents response rate data with PM1183 in patients with lung cancer‍​

Sept 12 (Reuters) - PHARMA MAR SA:

* NEW POSITIVE DATA ON PM1183 SEES RESPONSE RATE OF 36 PERCENT AS SINGLE AGENT IN PATIENTS WITH ADVANCED AND RELAPSED SMALL-CELL LUNG CANCER

* SAYS UP TO TODAY, THERE IS ONLY ONE APPROVED THERAPY, TOPOTECAN, IN RELAPSED DISEASE, THAT OFFERS A RESPONSE RATE OF BETWEEN 17 PERCENT AND 24 PERCENT ‍​ Source text: bit.ly/2wWZTNj

Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below